Role of monteleukast in the treatment of covid – 19 an overview
Abstract
Introduction: COVID – 19 infections that has shaken the world by leading into a significant health issue. World is in the need for effective therapies in order to improve clinical outcomes of patients. We must consider new approaches in the treatment of COVID-19. In order to bring effectiveness in treatment, it is important to know the exact pathogenesis of the virus so that it will pave a path for an efficient treatment.
Methods: To ensure comprehensive research and discuss the objective of the review of the study, literature collection was collected from the relevant published articles from databases such as “PubMed, Medline, and SCOPUS,”
Results: COVID-19 is linked with severe inflammation. Pro-inflammatory cytokine levels are elevated in the lung and in bronchial cells. Leukotrienes [LTs] are eicosanoids and inflammatory mediators. Leukotrienes are produced by various cell types which includes, leukocytes. Cysteinyl-leukotrienes (CysLTs) are involved in respiratory pathologies such as inflammation, thrombosis and vascular damage, and fibrotic remodeling.
Discussion: Hence there is a rational for LTs inhibition and montelukast usage in respiratory diseases beyond asthma. Various literatures suggest the use of LT receptor antagonist ‘Montelukast’ in COVID – 19 treatments.
Conclusion: This review article will discuss various aspects of Montelukast in COVID – 19 treatments and reviews the properties of montelukast that could be beneficial in the treatment of COVID-19.
Downloads
References
Aigner, L., Pietrantonio, F., Bessa de Sousa, D. M., Michael, J., Schuster, D., Reitsamer, H. A., Zerbe, H., & Studnicka, M. (2020). The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic. Frontiers in molecular biosciences, 7, 610132.
Al-Kuraishy, H. M., Al-Gareeb, A. I., Almulaiky, Y. Q., Cruz-Martins, N., & El-Saber Batiha, G. (2021). Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity. European journal of pharmacology, 904, 174196.
Almerie, M. Q., & Kerrigan, D. D. (2020). The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. Medical hypotheses, 143, 109883.
Anderson, R., Theron, A. J., Gravett, C. M., Steel, H. C., Tintinger, G. R., & Feldman, C. (2009). Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. British journal of pharmacology, 156(1), 105–115.
Barre, J., Sabatier, J. M., & Annweiler, C. (2020). Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence. Frontiers in pharmacology, 11, 1344.
Chams, N., Chams, S., Badran, R., Shams, A., Araji, A., Raad, M., Mukhopadhyay, S., Stroberg, E., Duval, E. J., Barton, L. M., & Hajj Hussein, I. (2020). COVID-19: A Multidisciplinary Review. Frontiers in public health, 8, 383.
Dogan, H. O., Şenol, O., Bolat, S., Yıldız, Ş. N., Buyuktuna, S. A., Sarıismailoglu, R., Dogan, K., Hasbek, M., & Hekim, S. N. (2021). Understanding the pathophysiological changes via untargeted metabolomics in COVID-19 patients. Journal of medical virology, 93(4), 2340–2349.
Downing, S., Chauhan, V., Chaudry, I. H., Galwankar, S., Sharma, P., & Stawicki, S. P. (2020). Colchicine, Aspirin, and Montelukast - A Case of Successful Combined Pharmacotherapy for Adult Multisystem Inflammatory Syndrome in COVID-19. Journal of global infectious diseases, 12(4), 221–224.
Fidan, C., & Aydogdu, A. (2020). As a potential treatment of COVID-19: Montelukast. Medical hypotheses, 142, 109828.
Funk, C. D., & Ardakani, A. (2020). A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes. Frontiers in pharmacology, 11, 1214.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C., & Pohlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271–280.e8.
Khan, A. R., Misdary, C., Yegya-Raman, N., Kim, S., Narayanan, N., Siddiqui, S., Salgame, P., Radbel, J., Groote, F., Michel, C., Mehnert, J., Hernandez, C., Braciale, T., Malhotra, J., Gentile, M. A., & Jabbour, S. K. (2022). Montelukast in hospitalized patients diagnosed with COVID-19. The Journal of asthma : official journal of the Association for the Care of Asthma, 59(4), 780–786.
Lima-Morales, R., Mendez-Hernandez, P., Flores, Y. N., Osorno-Romero, P., Sancho-Hernandez, C. R., Cuecuecha-Rugerio, E., Nava-Zamora, A., Hernandez-Galdamez, D. R., Romo-Duenas, D. K., & Salmeron, J. (2021). Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 105, 598–605.
Ludwig, S., & Planz, O. (2008). Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy. Biological chemistry, 389(10), 1307–1312.
Maeba, S., Ichiyama, T., Ueno, Y., Makata, H., Matsubara, T., & Furukawa, S. (2005). Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 94(6), 670–674.
Merad, M., & Martin, J. C. (2020). Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature reviews. Immunology, 20(6), 355–362.
Norouzi, A. (2020). Treatment of SARS-CoV-2 (COVID-19) cases by the oral administration of montelukast tablets. Bionatura, 5(4), 1305-1307.
Raymond, M., Ching-A-Sue, G., Oliver, V. H. (2020) Mast cell stabilisers, leukotriene antagonists and antihistamines: A rapid review of effectiveness in COVID-19. Pan American Health Organisation.
Sanghai, N., & Tranmer, G. K. (2020). Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms. Drug discovery today, 25(12), 2076–2079.
Scaife, A., Miller, D., Spiteri-Cornish, D., Turner, S. W., Devereux, G. S., & Walsh, G. M. (2013). Inhibitory effects of Montelukast on mediator release by nasal epithelial cells from asthmatic subjects with or without allergic rhinitis. Respiratory medicine, 107(12), 1859–1865.
Suceveanu, A. I., Mazilu, L., Suceveanu, A. P., Parepa, I., Dumitrescu, I. B., Dragoi, C. M., Nicolae, A. C., Botea, F., Voinea, F., Traian, G., Burcea-Dragomiroiu, A. L. (2020). Assertion for montelukast in the covid-19 pandemics. Farmacia, 68(4), 579-85.
Tavares, M., Farraia, M., Silva, S., Ribeiro, A. M., Severo, M., Paciência, I., Ribeiro, R., Hespanhol, V., Guimaraes, T., Almeida, J., Magro, F., Sarmento, A., Oliveira, A. M., & Moreira, A. (2021). Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial. Porto biomedical journal, 6(2), e134.
Topaloglu, N., Olgun Yıldızeli, S., Şener, G., Lacin, T., Sehirli, O., Bozkurtlar, E., Celikel, C., & Ceyhan, B. (2018). Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin-induced pulmonary fibrosis. Turk gogus kalp damar cerrahisi dergisi, 26(4), 588–597.
Copyright (c) 2022 Thurka S, Sravani Marpaka, Chakradhar T, Swati Negi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
